NASDAQ: ALNYAlnylam Pharmaceuticals Inc Stock Ownership - Who owns Alnylam Pharmaceuticals?
Insider buying vs selling
Have Alnylam Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Pushkal Garg | EVP Chief RD | 2025-10-03 | 898 | $451.76 | $405.68kSell |
| Pushkal Garg | EVP Chief RD | 2025-10-03 | 417 | $453.51 | $189.11kSell |
| Pushkal Garg | EVP Chief RD | 2025-10-03 | 215 | $454.37 | $97.69kSell |
| Pushkal Garg | EVP Chief RD | 2025-10-03 | 682 | $449.99 | $306.89kSell |
| Pushkal Garg | EVP Chief RD | 2025-10-03 | 810 | $450.63 | $365.01kSell |
| Pushkal Garg | EVP Chief RD | 2025-10-02 | 180 | $448.77 | $80.78kSell |
| Pushkal Garg | EVP Chief RD | 2025-10-02 | 56 | $447.92 | $25.08kSell |
| Pushkal Garg | EVP Chief RD | 2025-10-02 | 115 | $446.53 | $51.35kSell |
| Tolga Tanguler | EVP Chief Commercial Officer | 2025-10-02 | 1 | $457.64 | $457.64Sell |
| Tolga Tanguler | EVP Chief Commercial Officer | 2025-10-02 | 70 | $457.43 | $32.02kSell |
ALNY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when ALNY insiders and whales buy or sell their stock.
ALNY Shareholders
What type of owners hold Alnylam Pharmaceuticals Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Capital World Investors | 12.82% | 16,805,007 | $8.08B | Institution |
| Fmr LLC | 12.06% | 15,806,521 | $7.60B | Institution |
| Ag Novartis | 11.29% | 14,800,620 | $7.12B | Insider |
| Vanguard Group Inc | 10.14% | 13,297,139 | $6.40B | Institution |
| Sanofi | 8.05% | 10,554,134 | $5.08B | Insider |
| Blackrock Inc | 7.61% | 9,980,163 | $4.80B | Institution |
| Capital Research Global Investors | 5.49% | 7,191,656 | $3.46B | Institution |
| Regeneron Pharmaceuticals Inc | 3.39% | 4,444,445 | $2.14B | Institution |
| T Rowe Price Investment Management Inc | 3.27% | 4,281,279 | $2.06B | Institution |
| Dodge Cox | 2.44% | 3,197,096 | $1.54B | Institution |
ALNY vs Biotech Stocks
Alnylam Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.